GlassScriptPhysician profile
Mohammed Hassan
NPI 1083877682
$7,293.27
in general payments reported to CMS, 2019-2025
22 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $126 · 2021: $84.37 · 2022: $1,590 · 2023: $1,889 · 2024: $1,116 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,623 · Travel and Lodging: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.49 |
| Travel and Lodging | $934.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $2,804.91 | 2022-2025 | Gore Tag Conformable Thoracic Stent Graft, Gore Tag Thoracic Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Abiomed | $940.47 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $887.11 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $351.28 | 2019-2022 | |
| Coastal Medical Technologies LLC | $337.55 | 2024-2025 | |
| Medtronic, INC. | $302.44 | 2021-2024 | Corevalve Evolut R, Endurant Iis, Valiant Captivia |
| Actelion Pharmaceuticals US, INC. | $287.19 | 2023-2024 | Opsumit, Uptravi |
| Getinge USA Sales, LLC | $259.32 | 2022-2025 | Acrobat-I Stabilizer, Vasoview Hemopro 2, Cardioroot |
| Astrazeneca Pharmaceuticals LP | $226.83 | 2023-2025 | Fasenra |
| Abbvie INC. | $209.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.40 | 2023-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2023 | Cuvitru |
| Glaxosmithkline, LLC. | $124.99 | 2023 | |
| Medtronic Vascular, INC. | $120.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.84 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $28.63 | 2022 | |
| Artivion, INC. | $23.62 | 2022 | |
| Genentech USA, INC. | $22.89 | 2023 | Tecentriq, Alecensa |
| Lsi Solutions INC | $21.76 | 2023 | Cor Knot |
| Astellas Pharma US INC | $20.56 | 2025 | Vyloy |
| Integra Lifesciences Corporation | $16.22 | 2019 | |
| Endologix LLC | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.